You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

486 Results
Drug
Other Name(s): Rituxan® SC
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Jun 2025
Guidelines and Advice
Status: Current
ID: GL 2-33
Version: 2
Updated
Jun 2025
The following information answers many of the questions primary care physicians commonly ask about the Screening Activity Report and the included...
Les informations suivantes répondent à de nombreuses questions fréquemment posées par les médecins de première ligne au sujet du rapport d'activité...
A variety of screening tools and resources are available to support the screening activities of primary care providers, nurses and specialists.

Pages